Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:35:08 2025-07-11 am EDT			5-day change	1st Jan Change
33.70 ^USD	-1.68%		+12.61%	-19.02%

Jul. 10	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Jul. 10	Sector Update: Health Care Stocks Rise Thursday Afternoon	MT

US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults

Published on 06/12/2025 at 19:33

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Moderna, Inc.

Sector Update: Health Care Stocks Rise Late Afternoon	Jul. 10	MT
Sector Update: Health Care Stocks Rise Thursday Afternoon	Jul. 10	MT
Sector Update: Health Care	Jul. 10	MT
Top Midday Stories: MP Materials Partners With DoD on Rare Earth Magnet Supply Chain; Delta Restores Full-Year Guidance	Jul. 10	MT
BioNTech, Pfizer Urge UK Court to Overturn Moderna Vaccine Patent Ruling	Jul. 10	MT
Moderna Wins US FDA Clearance for Updated COVID-19 Vaccine for At-risk Children	Jul. 10	MT
Pfizer, BioNTech Appeal London Court Ruling Over Moderna mRNA Patent Dispute	Jul. 10	MT
Moderna: Spikevax approved for children at increased risk	Jul. 10	CF
Moderna Receives FDA Approval for Spikevax Vaccine in Children Aged Six Months to 11 Years	Jul. 10	MT
Moderna gets full US approval for COVID shot in at-risk children 6 months and older	Jul. 10	RE
AI Mania Masks Trade War Risks	Jul. 10
Moderna gets full US approval for COVID-19 vaccine in children 6 months and older	Jul. 10	RE
Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win	Jul. 10	RE
Wall St stocks edge lower as investors look for tariff clarity	Jul. 08	RE
Wall St is mixed as investors monitor Trump's latest tariff moves	Jul. 08	RE
US CDC ends emergency bird flu response as infections decline	Jul. 07	RE
US CDC accepts ousted vaccine panel's recommendations for RSV, meningococcal shots	Jul. 02	RE
US CDC accepts ousted vaccine panel's recommendations for RSV, meningococcal shots	Jul. 02	RE
Moderna, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 10:00 AM	Jul. 01
Health Care Up as Budget Bill Fears Ease -- Health Care Roundup	Jun. 30	DJ
Moderna, Inc.(NasdaqGS:MRNA) added to Russell Midcap Value Index	Jun. 30	CI
Sector Update: Health Care Stocks Higher Late Afternoon	Jun. 30	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	Jun. 30	MT
Sector Update: Health Care	Jun. 30	MT
Top Midday Stories: Hewlett Packard, Juniper Settle Antitrust Suit With DOJ; Home Depot Unit Acquires GMS for $5.5 Billion	Jun. 30	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Employees

5,800

Sector

Pharmaceuticals

Calendar

Jul. 30 - Q2 2025 Earnings Release (Projected)

More about the company